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1. Introduction 
The advent of the omics area has created new research systems, including genomics, 
proteomics, metabolomics, as well as the associated bio-informatics science, and databases. 
At the same time, progress in traditional western medical research has reached a bottleneck, 
as single compound drugs are costly to create, synthesize, or engineer. If we are to see real 
and sustained progress in research, we must find approaches to utilize traditional remedies 
to develop advanced medicines.  
Instrumental systems for transcriptome, including the microarray of different messenger 
RNA, microRNA and other non-gene sequence-related RNA products, have already been 
developed; functional genomics studies using these systems have been remarkably 
successful. However, the candidate genes involved in specific functions often need further 
verifications for revealing their roles in the signal pathways. The difficulty may also arise 
from the high variety and seemingly unrelated responsive genes and complex signaling or 
regulatory systems involved.  
Proteomic analysis has its disadvantages, although two-dimensional (2-D) gels can display 
viable candidate proteins for study. Up to two thousand proteins of biological systems can 
often be analyzed in sensitive 2-D gel systems. There are other proteins, such as cytokines or 
chemokines of most leukocyte cells are expressed at relatively low levels, and often are not 
detectable by 2-D gels. More sensitive methods, such as LC/MS and other fractionation 
systems, need to be used for such cases.  
Metabolomics faces an even greater challenge: a 2-D or one run display of the components 
of a metabolome has not been defined and cannot be systematically evaluated. Therefore, 
sequential analyses, e.g. the LC/MS followed by NMR, were developed to address the 
“overall” or more comprehensive picture of metabolomes.  
Several phyto-medicinal studies, including some in traditional Chinese herbal medicine 
(TCM), have been considered as metabolome investigations. New strategies employing 
omics approaches may be especially useful for phytomedicinal research, as conventional 
phytomedicines often employ multiple components and they often are believed to interact 
with multiple molecular targets related to cellular and physiological (e.g., immune-
modulatory) effects. In order to successfully evaluate the effects of phytomedicines, various 
omics approaches are being systematically combined. New computational and cross-
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disciplinary analyses will be required for most experimental biology studies. Some 
examples of systematic and technical considerations, in terms of research into the immune-
modulatory and anti-inflammatory effects using the omics approaches, are addressed in this 
brief review.  
1.1 Importance of systems biology and bioinformatics 
Scientists investigate medicinal plants in search of regulatory genes and metabolites that can 
affect, modulate or upgrade the biological and metabolic processes, which in turn can confer 
specific physiological or pharmacological functions. Recently, various high-output 
technologies, including genomics, transcriptomics, proteomics and metabolomics, are 
employed in such research effort [1-3]. Bioinformatics and systems biology approaches are 
considered by many as needed to organize, manage, process, and understand the vast 
amounts of data obtained in various omics studies [4-8]. In addition, systems biology is 
aimed at understanding complex biology by integrating omics data from various sources for 
network analysis, for evaluating the holistic system as a whole, as experimental results from 
omics studies are most often not obtained or isolated as a single set of data points or evens 
[9]. By analyzing the omics data, bioinformatics tools can help upgrade new approaches for 
classifying and authenticating potential medicinal plants, identifying new bioactive 
phytochemicals or compounds, and even improving medicinal plant species or cultivars 
that can tolerate stressful environmental challenges.  
The human immune system, as we currently conceptualize it, is under the tight control of a 
complex network of regulatory genes, RNAs, modulatory proteins and stimulatory 
metabolites. Past studies have often focused on understanding the roles of specific genes in 
immune responses. To associate expression changes with immunological conditions such as 
suppression, cancer, or autoimmunity, we can investigate the interrelationship of the up- 
and down-regulation of genes or proteins patterns. Using microarray analysis and 
comparative genomics, Hutton et al. [10] have identified genes and their regulatory 
elements responsible for maintenance, differentiation, and the general functioning of 
specific immune systems. In addition, most of the expression pattern of genes is related to 
the biological role and effects of the products of genes, and a similar statement may be made 
for protein expression [11]. Taken together, evaluation of gene and protein expression 
profiles may lead us to identify links between specific genes or proteins and the associated 
specific immuno-modularory effects. Moreover, omics technologies may also be employed 
to address our views of the often-used concepts in immunology, such as: molecular 
dynamics in response to specific stimulations or alterations of the molecular state of targeted 
specific cells, in the hypothesis-driven research approach [12]. For instance, in the drug 
discovery process, pharmaceutical companies have used various microarray systems as 
screening tools to eliminate compounds that have molecular indications of toxicities before 
preclinical and clinical testing [13]. In basic research, omics technologies have continually 
improved our understanding on how drugs can regulate the immune system as well as of a 
variety of issues in mechanistic or hypothesis-driven research [14-17]. The data obtained 
from these studies not only may have significant impact on the future directions of those 
specific lines of research but also may improve our understanding of the specific immuno-
modulatory regulation of given drugs. 
Bioinformatics is the application of computational tools for biological sciences; its major aim 
is the management and interpretation of biological data [18]. It has been an essential tool for 
www.intechopen.com
 
Immuno-Modulatory Effects of Phytomedicines Evaluated Using Omics Approaches 
 
291 
fully integrating and multi-disciplinary understanding the processes in various biological 
areas [19]. Among them, understanding omics data requires both common statistical and 
machine-learning methods, because the data are usually in high-dimensional form and 
complexity. On the other hand, as compared with other biomedical and agricultural areas, 
the study of omics and its use for research into medicinal plants are still in its infant stage. 
Given the demand for studies on immuno-modulatory effects of herbal medicines, this 
chapter introduces and summarizes the applications of some omics approaches and specific 
bioinformatics tools for investigating phytomedicines. 
1.2 Omics technologies 
The technology platforms generally used in systems biology research, including 
transcriptomics, proteomics and metabolomics, have enabled us to study living systems 
from a holistic or integrative perspective through revealing profiles of multitudinous 
biochemical components (Figure 1); it also opens up a unique opportunity to reinvestigate 
phytomedicines [20]. The revolution of genomics research and technology development has 
yielded complete or draft DNA sequence maps for a spectrum of species including human, 
mouse and a serious of model organisms. Having the genomic data available, many new 
‘drug-able’ targets based on transcriptomics study have been identified, opening up new 
insights into explanations of biological systems at a global scale. Additionally, through 
proteomics, we are witnessing the development of wonderful and multi-application tools 
for studying various signaling or mechanism systems at the level of proteins and protein–
protein interactions [20, 21]. In the meantime, studies on glycol-biology and bioactive 
polysaccharides are making great leaps in glycomics research; similarly, studies on 
regulation and metabolic control of a spectrum of lipids are creating new approaches for 
“lipidomics”. The recent wave of data from genomics and proteomics has precipitated the 
measurement of increasingly a group or spectrum of elements to provide a systems 
approach, especially at the level of metabolites and for the field of metabolomics. 
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Fig. 1. The different levels of measurement in a systems biology approach. 
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Although omics are defined in several different ways today, in our opinion these systems 
provide “an integrated approach to study biological systems not only for the intracellular, 
but also at the cellular, organic and the whole body or organismic levels or networks, 
through measuring and integrating the genomic, proteomic and metabolic data” in a global 
consideration manner (Figure 1) [20, 22, 23]. 
In the search for new phyto-medicines, the necessary purification of single active 
components has been in general successful, whereas synergetic effects of mixtures of 
components (e.g., crude plant extracts) remain difficult to evaluate. Utilizing omics 
technology, scientists hope to develop methods and models to detect and observe the effects 
of complex mixtures such as various plant tissue extracts traditionally used in herbal 
medicines. This applies especially to approaches employing metabolomics which adress 
comprehensive phytochemical profiling, bioactivity phenotyping, sophisticated bio-organic 
chemistry instrumentation, and new cross-talk experimental designs. This scenario needs 
not only advancement in natural product research, but also revolutionary strategy in the 
development of molecular pharmacology-based herbal medicines [20]. 
1.3 Phytomics 
The term “Phytomics” has been previously created to the “omics-based approach” for 
studying chemical compositions in plant (Kung PC et al., 2003), specifically: using 
bioinformatics and/or statistics to address qualitative and quantitative aspects of chemical 
compositions or profiles of the plant metabolites of our interest; or to develop databases for 
addressing such aspects [24].  
2. Transcriptomics study on medicinal plant research 
2.1 Application of DNA microarrays in toxicogenomics, pharmacogenomics and 
functional genomics studies of bioactivities from medicinal plants 
Recent advances in genomics-based identification of responsive gene clusters, gene families or 
gene polymorphisms associated, with immune system dysfunction have helped to address 
some basic issues in immunology, and have begun to expand our understanding of immune-
related disease processes [13]. The application of omics technologies in toxicological research 
(toxicogenomics) provided new insights into mechanisms of action, as well as data likely to be 
useful for risk assessment [13, 25]. Gene chips or microarrays are already employed in 
immunotoxicology research to identify biochemical pathways that are altered by specific 
chemical exposures. For example, trichothecene mycotoxin deoxynivalenol has been shown in 
mice to modulate splenic early responsive genes, which are functionally related to immunity, 
inflammation and chemotaxis [15, 26], indicating the importance of innate immune systems, 
including macrophages, granulocytes, neutrophils and various soluble mediators released in 
the inflammatory response activated by the hexachlorobenzene treatment. For basic research, a 
number of mechanistic studies have been performed towards gaining a comprehensive 
understanding of the immunomodulatory properties of potential new drugs or drug leads. 
Thymic atrophy, for instance, appears to be mediated in part by 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD)-induced apoptosis [27]. Using an apoptosis-specific cDNA array combined 
with promoter analyses, specific and novel gene targets have been shown to enhance negative 
selection in the thymus and thus result in TCDD-induced thymic atrophy [16]. In a separate 
study, cDNA microarray analyses were utilized to evaluate the TCDD regulation of Fas ligand 
(FasL) promoter activity through modulation via NF-κB in thymic stromal cells and the 
subsequent initiation of the apoptotic pathway in thymic T cells [28].  
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During the past decade there has been a paradigm shift from utilizing single-target drugs to 
multi-target drugs [29, 30]. The concept of multi-targeted therapy was once believed to 
better represent the conventional herbal medicine treatments that often employ multi-
component plant tissue extracts as natural products mixtures. However, very few phyto-
medicinal products have clear or systematic documentations comparable to that of 
chemically synthesized drugs as single chemical compound. This situation has hampered 
our ability to predict precise or specific molecular targets, signaling or action mechanisms of 
activity, and possible side effects of “herbal drug” products [30]. With these requirements 
for botanical and clinical uses, a validated genomics and metabolomics approach in 
combination can be applied to quantify specific chemical markers and, subsequently, to 
obtain chemically standardized extracts [31]. In addition, researchers have witnessed a wide 
range of molecular mechanisms governing various cellular and tissue behaviors. The 
genomics approach with integrations of large and diverse sources of gene, protein and 
metabolite expression information will assist in making comprehensive and integrated 
predictions about the pharmacological effects of plant natural products [32].  
While numerous laboratories use genomics in their investigation of underlying mechanisms 
of immunotoxicity, few have employed genomic analyses as a screening tool. Many 
differentially expressed genes are known to play a role in apoptosis, host defense, cell 
growth and differentiation, and trafficking of specific cells in body fluid systems. In the 
spleen, these may include the up-regulation of IL-18, lymphotoxin B receptor, and colony-
stimulating factor receptor, and down-regulation of RANTES and histocompatibility 
antigens [15, 33-35]. In the thymus, gene changes included the down-regulation of nuclear 
factor of activated T cells, interferon gamma receptor, and T cell transcription factor 7, and 
the up-regulation of caspase 1 and ApoE. These findings are consistent with alterations 
previously observed in specific immune functions [34, 36] and could further expand our 
knowledge at gene regulation level. 
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Fig. 2. DNA microarray applications in natural product drug discovery and development 
[37].  
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Applications of DNA microarray technologies in herbal drug research may be classified into 
three major areas. Firstly, it can be used in pharmacodynamics to aid the discovery of new 
diagnostic indicators and biomarkers for therapeutic response, elucidation of molecular 
mechanisms of herbal action, its formulations or its phytochemical components, and in 
identification and validation of new molecular targets for herbal drug development (Figure 
2) [30], [37]. Secondly, it is applicable in toxicogenomics for predicting side effects of a 
medicinal herb or phytomedicine lead drug during preclinical activity and safety studies, 
conferring drug safety or resistance [38]. Thirdly, it is useful for botanical or plant 
identification and authentication of crude plant materials as part of an effort and regulatory 
system for standardization and quality control [39]. Given these considerations, DNA 
microarrays may thus offer powerful predictive functions at different stages of a typical 
drug/phytomedicine discovery pipeline. 
2.2 Immuno-modulatory effects of different phyto-compounds/candidate 
phytomedicines 
With the increased demand for validated herbal products for medicinal use comes the need 
to better understand the molecular mechanisms of their biological activities. Although many 
reputed herbal drugs are investigated at the molecular level, it remains difficult to realize 
the exact targets of individual phytochemical components and how these molecules together 
or independently can contribute to specific immuno-modulatory effects. Here, we discuss 
findings from some of the recent studies on microarray-based gene expression aimed at 
elucidating immune-regulatory mechanisms of pure phytochemicals as well as specific 
herbal extracts. 
2.2.1 Purified compounds or specific phytochemical groups 
The Chinese medicinal herb root Tripterygium hypoglaucum has been subjected to cDNA 
microarrays containing 3000 human genes (derived from a leukocyte cDNA library) in order 
to study its role in apoptosis-inducing activity of plant alkaloids. Apoptosis induced by 
these T. hypoglaucum alkaloids was shown to be mediated through c-myc and NF-kappa B 
signaling pathways [40]. In an animal model of aged rat, gene chip (Rat Genome U34A) 
analysis was applied to evaluate the gene regulatory pattern of Epimedium flavonoids in 
immune homeostasis. Epimedium flavonoids were found to reverse the “abnormal” or aging 
changes, allowing reconstruction of a beneficial equilibrium in gene expression and thus 
further remodeling of the immunohomeostasis in the aged rat [41]. Taken together, results 
from these studies indicate that the expression pattern characterized by up-regulation of 
specific apoptosis-promoting genes and down-regulation of certain apoptosis-inhibiting 
genes can be considered as important genomic background of an immunohomeostasis 
imbalance [30]. 
A traditional Chinese medicinal (TCM) herb prescription, Si-Jun-Zi decoction (SJZD), has 
been administered in a clinical setting to patients with disorders of the digestive system. 
Previous studies have indicated that the polysaccharides of SJZD are active components of 
the phyto-extract mixture in improving gastrointestinal function and immunity [42]. SJZD 
polysaccharides also had a protective effect and enhanced re-epithelialization on wounded 
IEC-6 cells. To further elucidate this effect at the molecular level, an oligonucleotide 
microarray was employed to study differential gene expression of SJZD-treated IEC-6 cells. 
There was, indeed, increased expression of genes encoding for ion channels and 
transporters, known as critical to cell migration and restoration of wounded cells, 
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suggesting a mechanism for re-epithelialization as well as improved immunity [43]. These 
studies demonstrate the useful approach of functional genomics for research into 
modernization of TCM. 
Shikonin and its derivatives, from the TCM-claimed medicinal herb Lithospermum 
erythrorhizon, have been shown to possess numerous beneficial pharmacological properties, 
including anti-inflammatory and antitumor properties [44, 45]. In our previous report, 
shikonin was shown to confer a potent bioactivity on suppression of TNF-α promoter 
activity [46]. Additionally, shikonin was found to mediate cytokine expression through 
inactivation of the RNA-activated protein kinase (PKR) pathway [46]. It was also suggested 
from the reports that regulation of TNF-α pre-mRNA splicing may constitute a promising 
target for future anti-inflammatory application [47]. Moreover, the functional genomic 
(DNA microarray) analysis on the cellular immunological effects of shikonin effectively 
distinguished the complex and specific bioactivities of this phyto-compound in human 
monocytes [48]. Further, ubiquitin pathway regulator, e.g., Rad23A, was also identified as 
possible key regulators for this shikonin effect [48]. A transcriptomics approach has 
therefore been instrumental in screening immune-modulatory effects of noteworthy 
phytocompounds. These studies have set useful examples for future systematization of key 
traditional herbal medicine-derived phytomedicines. 
2.2.2 Medicinal herbal extracts 
Screening of the human genome for TNF-α-inducible genes has been used to identify the anti-
inflammatory effects of 5-Loxin, a standardized Boswellia serrata extract, in microvascular 
endothelial cells [49, 50]. It was shown that 113 out of the 522 TNF-α-induced genes were 
responsive to 5-Loxin treatment. These genes are directly or apparently related to 
inflammation, cell adhesion, and proteolysis. These robust 5-Loxin-sensitive candidate genes 
were subjected to further evaluation for molecular signaling, and this processing led to the 
suggestion of the primary 5-Loxin-sensitive TNF-α-inducible pathways. Mechanistically, 5-
Loxin can completely inhibit VCAM-1 expression, and TNF-α can cause inflammation by 
strongly up-regulating the expression of this adhesion molecule VCAM-1. [49]. 
Recently, genomics analysis has also evolved for evaluation of the efficacy of bioactive 
chemicals in natural health products as therapeutics, for instance, with regard to the 
alleviation of specific inflammatory activities in human airway epithelial cells [33]. In 
addition, one application of gene expression profiling in this research field may be the 
growing appreciation for the multiple and pivotal roles played by various dendritic cells 
(DCs) in initiating and regulating a spectrum of immune responses. These cells are 
responsible for recognizing and processing various antigens and their ultimate presentation 
to specific immune cell (e.g., T cells) systems [51-53]. It has been well established that DCs 
present in the epidermis (Langerhans cells (LCs)) are required for the presentation of 
chemical allergens at the skin’s surface, as well as for skin sensitization [54, 55]. 
Investigations by Enk and Katz [56] have revealed that topical exposure of mice to chemical 
allergens, but not to a non-sensitizing skin irritant, caused numerous changes in expression 
of cytokines and chemokines by LC and local epidermal cells. Among these changes 
recorded following allergen treatment was a rapid increase in LC expression of mRNA for 
interleukin-1β (IL-1β), a cutaneous cytokine necessary for the regulation of LC function and 
for skin sensitization [56-59]. These results concluded that changes in the expressions of IL-
1β by LC in response to chemical allergens might hence provide a practical and efficient in 
vitro approach for identifying skin-sensitizing chemicals [60]. 
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Genome-wide analysis has been adopted as a less selective approach for measuring the 
holistic or global changes in gene expression [17, 61-64]. It can be anticipated that the 
activation and functional maturation of DCs, as drastic cellular activities, are likely to be 
associated with changes in the levels of a spectrum of gene expressions that are responsible 
for: (a) intracellular metabolic processes; (b) control of cell motility (including those 
regulating intercellular communication and interactions with the tissue matrix); (c) cytokine 
and chemokine production, and (d) cell growth regulation and survival [17, 61]. Results of 
our previous studies on the immune-modulatory effects of a phytocompound mixture, 
extracted from the butanol fraction (BF) of a stem and leaf (S+L) extract of Echinacea 
Purpurea ([BF/S+L/Ep]), suggest that [BF/S+L/Ep] can effectively modulate DC mobility in 
vivo and related cellular physiology in the mouse immune system. In addition, [BF/S+L/Ep] 
modulated cell adhesion-, cell mobility-, cytokine- and NF-κB signaling- related activities in 
primary cultures of mouse DCs [17]. Similar study of Wang et al [60], have further shown 
that genes expressed in [BF/S+L/Ep]-treated human DCs revealed a key-signaling network 
involving a number of immune-modulatory molecules and lead to the activation of a 
downstream molecule, adenylate cyclase 8. These examples show that genomics approaches 
can be usefully employed for predicting candidate target molecules in future translational 
studies of phytochemicals, phytocompound mixtures, and medicinal herbal extracts.  
2.3 Use of cDNA microarray/ expression sequence tags (ESTs) for evaluating 
bioactivities of medicinal plants 
A transcriptome is the set of all detectable RNA molecules, including mRNA, tRNA, rRNA, 
and non-coding RNAs (e.g., siRNA, microRNA) produced in a group of test cells or tissues. 
By using the advanced transcriptomics, an organism’s entire transcriptome can now be 
effectively analyzed for many experimental systems. Technically, transcriptomics is a 
technology to reveal genome-wide gene expression profiles, patterns, integrated or 
segregated features or networks describing a global view or analysis of gene expression 
activities of the genome at the mRNA or regulatory RNA levels. These technologies 
comprise cDNA-AFLP, SAGE, cDNA microarray (or gene chip), oligonucleotide-microarray, 
and microRNA microarray [2]. Microarrays also have been used to detect gene expression 
changes of medicinal plants in a variety of developmental stages, geographic locations, 
natural growth environments, and/or cultivation conditions [2]. In phytomics studies, 
studies have aimed to identify the responsive genes that are regulated by active medicinal 
compounds, anti-pathogen infection, or adaptation to harsh environment [65].  
To design appropriate probe sequences for a DNA microarrays efficiently, we need to 
consider the genome sequence information for a specific organism in its entirety or with a 
definable set or subset. However, since only very limitted genomes of medicinal plants have 
currently been sequenced, one alternative is to gather the necessary transcriptome 
information, by generating or making use of existing expression sequence tags (ESTs) [66, 
67]. Increasing numbers of EST libraries from medicinal plants such as Panax quinquefolius 
[68], Huperzia serrata [69], P. Notoginseng [70], Rehmannia glutinosa [71], and Catharanthus 
roseus [72] have been recently obtained. An automatic system for large scale EST sequence 
retrieval, assembly, and functional and pathway analyses has been established [73]. This 
system has been successfully applied to analyzing both plant [74] and animal EST sequences 
[73, 75]. These EST and annotation systems have provided a good foundation for design of 
suitable arrays for representative genomes or focused transcriptomics, hence providing 
valuable information for genomic research into phytomedicine. 
www.intechopen.com
 
Immuno-Modulatory Effects of Phytomedicines Evaluated Using Omics Approaches 
 
297 
3. Proteomics studies on the research into medicinal plants 
3.1 Use and advancement of analytical and instrumentation systems: Two-
dimensional gel electrophoresis (2-DE), electrospray ionization, matrix-assisted laser 
desorption/ionization and surface-enhanced laser desorp  
The Nobel Prize in Chemistry for 2002 was shared between scientists from two research 
expertise: mass spectrometry (MS) and nuclear magnetic resonance (NMR). These 
revolutionary breakthroughs have allowed chemical biology to become one of the most 
significant scientific disciplines in recent years. Scientists can now rapidly and reliably 
identify most proteins in a relatively small sample and readily produce three-dimensional 
display and/or images of expressed protein molecules with highly resolution. With these 
advancements, various experimental approaches and technologies were developed to obtain 
a better understanding of proteins and their regulatory effects on molecular and cellular 
functions of various biological systems [76, 77]. Among them, technologies including two-
dimensional gel electrophoresis (2-DE) analysis [78, 79], matrix-assisted laser 
desorption/ionization (MALDI)- time-of-flight (TOF) [80] and Surface-Enhanced Laser 
Desorption/Ionization (SELDI)-TOF MS [81] have been broadly used in proteomics studies 
on the research of medicinal plants. 
3.2 Application of proteomics for research into traditional herbal medicine  
Proteomics technologies were applied to simultaneously study the function, organization, 
diversity, and the dynamic variety of total or a subset of proteins at the cellular or tissue 
levels [21]. The current integrative approach used in proteomics is in line with the practice 
and holistic philosophy of traditional Chinese medicine (TCM). Recent advances in 
multidimensional liquid chromatography, coupled with free-flow electrophoresis and 
capillary electrophoresis-based separation techniques, make it possible in separation of 
hundreds or even thousands of protein components in some medical plants [82, 83]. We 
may able now to explore an increased understanding of such complex mixtures and the 
reputed medicinal effects at the cellular and molecular levels through proteomics studies; it 
holds a key to the big demand for modernization and internationalization of a number of 
traditional phyto-medicines [83]. In this article, some of the proteomics approaches in TCM 
research and development are addressed, highlighting the application in mechanistic 
investigation of specific phytomedicines.  
Panax ginseng and Panax quinquefolius are two of the valued herbs widely used in TCM. 
Conventional separation methods were unable to distinguish the different plant parts 
(main root, lateral roots, rhizome head and epidermal tissues) between these two species. 
On the other hand, when 2-DE maps were employed, plant tissue samples containing 
distinct or common protein species (spots) can be easily discriminated or distinguished. 
Clearly, these potential protein biomarkers may also facilitate the identification processes 
for various medicinal plants that may be difficult to identify morphologically or 
anatomically [84].  
Numerous herbal medicines have been reported to have immunomodulatory and anti-
tumor effects in cancer cells [85-87]. Recent biological and pharmaceutical researches have 
shown that diosgenyl saponins may exert a large variety of biological functions, with a 
potential for use in cancer chemoprevention [88]. By using 2-DE, tryptic in-gel digestion and 
MALDI-TOF MS analysis, Wang et al. [89] suggested that dioscin, a saponin extracted from 
Polygonatum zanlanscianense Pamp., exhibited cytotoxicity towards human myeloblast 
leukemia HL-60 cells. This proteomics analysis also revealed that the expression of 
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mitochondria-associated proteins was substantially altered in HL-60 cells upon dioscin 
treatment, suggesting that mitochondria were the major cellular and organelle target of 
dioscin cytotoxicity. Moreover, the results indicated that other pathways were likely also 
involved in detected dioscin cytotoxicity, including phosphorylation-based cellular 
signaling, RNA-related protein synthesis, and oxidative stress processes. The study 
demonstrated the benefits of using a proteomics approach in anticancer phytomedicine 
research [90]. 
4. Metabolomics study on the research of medicinal plants 
Metabolomics, including both targeted and global metabolite profiling strategies, is 
rapidly becoming a popular and powerful approach of choice across a broad range of 
medical and biological sciences including systems biology, drug discovery, and molecular 
and cell biology [24]. Specifically for human metabolites, it is believed that at least 3,000 
metabolites that are essential for normal growth and development (primary metabolites) 
and >2000 secondary metabolites that are not essential for growth and development but 
may help fight off infection and other forms of stress on the body [91]. In addition, 
metabolomics are now being generally considered a vital component of the systems 
biology approach, in which it can reflect and connect the genotypes with diverse yet 
specific phenotypes of specific types of cells, tissues, or organs [91]. Within the past 
decade, the number of publications of metabolomics-related research articles has 
increased from roughly 40 in 2002 to 100, 170, 200 and >250 articles in the years 2004, 
2005, 2006 and 2007, respectively. Now it is estimated that >300 articles, with a general 
aim or study on metabolomics were published annually in 2010. Owing to its remarkable 
versatility, metabolomics is rapidly becoming a universal tool and key component in 
medical research [24]. Combined with genomics and proteomics technologies, systems 
biology research using metabolomics investigates characteristic molecular signatures for 
disease diagnosis, prognosis, and therapeutics [92]. This section reviews the recent 
developments in technology platforms and experimental approaches for metabolomics 
studies in the research of immunomodulatory properties of potential medicinal plants.  
4.1 Use of GC-MS, LC- MS, FT-IR and NMR technologies 
Currently, the term ‘metabolomics’ often can be used interchangeably with “metabolite 
profiling” because the type of one-step, two dimensional exhibition analysis used in 
genomics and proteonomics experiments is not possible at the present time, as the 
complexity of chemicals in most biological systems, especially in plants, is highly diversified 
and can be enormous [93]. The two basic approaches in metabolomics can be classified the 
targeted- and the global metabolite analyses. Targeted metabolite analysis, (or metabolite 
profiling), as the name implies, targets mainly a subset of metabolites in test sample, instead 
of a complete, global metabolome analysis, often by using a particular set of analytic 
technique(s) such as gas chromatography-mass spectrometry (GC-MS) and liquid 
chromatography–mass spectrometry (LC-MS), and yields an estimate of quantity [94]. 
Metabolomics approaches using GC–MS, LC–MS, or 2D NMR are effective tools for quality 
control of medicinal plants or herbal medicine products [95, 96]. As shown in Figure 3 [24], 
key aspects of the technology were assembled in many research institutions as “core 
labs/facilities” in the metabolomics approach for herbal medicine or other integrated 
research interest. Various other technical systems, methodologies or techniques, including 
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thin layer chromatography (TLC), Fourier transform infrared spectroscopy (FT-IR), Raman 
spectroscopy and NMR [97-99] are also important research facilities in the metabolite 
analysis arsenal. 
 
 
Fig. 3. Key features of metabolomics technologies employed for research into 
phytomedicines [24].  
Mass spectrometry is currently the most broadly applied technology in metabolomic 
studies. Among the variety of MS techniques, GC-MS has long been popularly used in 
metabolite profiling of plant extracts [100, 101]. Rapid, high-resolution 2D GC x GC-TOF MS 
has been employed in the phenotyping of natural rice variants [102] as well as for efficient 
quality control or analysis of herbal medicines [95]. Recently, capillary electrophoresis-MS 
has also been developed as a metabolomics tool, capable of simultaneously analyzing over 
1,000 charged chemical species, a technique that is expected to create a number of obvious 
applications in processing and characterization of various biological samples [95]. A 
shotgun approach using MALDI-TOF/TOF MS has recently been established for rapid 
analysis of negatively charged metabolites in mammalian tissues to: (a) facilitate the 
detection of low-abundant metabolites such as cAMP, cGMP, and IP3; and (b) discriminate 
isomeric molecular species [103]. In addition, novel instrumentation/equipment set ups 
developed recently, such as Fourier Transform Ion Cyclotron Resonance Mass Spectrometry 
(FT-MS), represents a quantum jump in the new capabilities of mass spectrometers for 
metabolite analysis. Due to the exceptionally high resolution of these instruments, 
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metabolites with mass differences of less than 2 ppm can now be separated on a 
chromatographic time scale (Van der Greef et al., 2004). The accurate results obtained can 
help reveal elemental compositions, which often enable unequivocal metabolite 
identification. 
Remarkable recent developments in analytical biochemistry regarding the detection and 
characterization of compounds with small molecular mass, such as MS and high-field NMR 
coupled with user-friendly multivariate statistics, have led to highly efficient systems for 
comprehensive analysis of the metabolite data matrices generated by metabolomics 
experiments [104]. One-dimensional (1D) NMR spectrometry has shown its capability for 
high-output analysis and classification of chemically similar groups of test samples. At the 
same time, the large numbers of overlapping peaks generated by such method may also 
hinder in some case accurate identification of specific metabolites. Recently, a replacement 
for the 1D 1H NMR spectroscopic technology also has been developed: a two-dimensional 
(2D) 1H–13C NMR strategy (fast metabolite quantification, FMQ, by NMR), was developed 
for analyzing metabolites as multivariate statistical objects [105]. 
The new ‘hyphenated’ techniques that combine in assay sequence various forms of liquid 
chromatography with NMR, such as HPLC-SPENMR, have effectively improved the 
sensitivity of NMR analyses and can be employed to characterize both high- and low-
abundant metabolites in complex crude plant extracts [106, 107]. 
4.2 Metabolomics research in medicinal chemistry studies 
Diverse secondary plant metabolites are believed to have evolved through continuous 
interactions with challenging and predominantly hostile environments, including both 
abiotic and biotic stresses. When these features are coupled with characteristic species and 
agronomic differences, various phyto-chemicals as secondary metabolites generally can 
confer various specific bioactivities related to their biochemical structures [108]. These 
bioactivities apparently can help the host plants to defend specific plant pathogens and to 
reduce a spectrum of abiotic stresses, e.g., drought, heat and saline conditions. Interestingly, 
these secondary plant metabolites often were also found to confer potent and valuable 
bioactivities for defending human sickness, including viral, cancerous and inflammatory 
diseases. Some well-known cancer chemotherapeutic drugs have been initially derived from 
plant secondary metabolites, such as paclitaxel (taxol), camptothecin (irinotecan, topotecan), 
and podophyllotoxins (etoposide, teniposide) [24, 109]. Recent re-recognization of the vast 
potential of plant secondary metabolites or natural products to serve as lead compounds for 
drug discovery and development, or as various general health care products, has renewed a 
lot of interest in pharmaceutical and nutraceutical research. De novo combinational 
chemistry has so far produced only a very limited number of novel drugs, the natural 
products and their derivatives are still considered by many scientists to be the primary 
source of leads for drug development [110]. In this area, the use of whole plants or their 
extracts as medicines gave way to the isolation of active phyto-compounds, beginning in the 
early 19th century with the isolation of morphine from opium. In such a reductionist 
approach, however, single active phytocompounds may often be not identifiable because of 
their low abundance in test plant extracts, or alternatively, a spectrum of pharmacological 
efficacy traditionally observed arises only as a synergistic action of the multiple but specific 
ingredients present in a single plant or even from a multiple medicinal plant formulation, as 
in TCM [111, 112].  
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To efficiently link the flood of experimental data and specific metabolites or general 
metabolite profiles information to biology and metabolism study systems, traditional 
bioinformatics is being combined with cheminformatics to generate a basic computational 
infrastructure for analysis of metabolomics [113, 114]. A number of metabolomics 
databases, some based on both chemical and biological/biochemical data, have been 
made publicly available [114]. The Human Metabolome Database (HMDB) is currently the 
largest and most complete database in breadth and depth, offering spectral, physico-
chemical, clinical, biochemical, genomic, and metabolism information for a library of 
>2500 known human metabolites [115, 116]. Other databases include the BioMagResBank 
(BMRB) with an emphasis on NMR data (>270 pure compounds), the Madison 
Metabolomics Consortium Database (MMCD) which presents MS and/or NMR data on 
more than 10,000 metabolites [117], and the Golm Metabolome Database (GMD) which 
has been specifically designed for plant research and utilizes GC–MS data [118]. 
Additionally, Wishart [113] has reviewed the development of algorithms and innovations 
in informatics concerning data reduction, normalization, and alignment that offer 
sufficient biological insight into metabolic profiles.  
4.3 Metabolomics approach applied to research into immuno-modulatory effects of 
phytomedicine 
It is now generally accepted that chronic inflammation is a key factor in the development of 
many types of cancers. Natural products, especially from plants, were once popular choices 
in cancer therapeutics based on their immunosuppressive or anti-inflammatory effects [110, 
119-121]. Recently, metabolomics has been effectively used to characterize and monitor 
carcinogenesis activities in mouse models [122]. In addressing oncology metabolomics, 
NMR was used to target biomarkers for prostate cancer by analyzing metabolites with anti-
inflammatory effects in the development and progression of this cancer for better future 
management [123, 124]. This metabolomics approach has also been successfully 
implemented to monitor the metabolism in human brain, liver tumors, lymphomas, and 
colon cancers [125].  
5. Comparative and bioinformatics tools for omics studies 
5.1 Ingenuity (http://www.ingenuity.com/) 
Functional genomics experimental approaches were employed in our previous studies on the 
modulatory effect of Echinacea plant extracts (e.g., the butanol-fractionated Leaf and Stem 
tissue extract designated as BF/S+L/Ep) on both mouse and human DCs [17, 63, 64]. Using 
the same defined phytochemical extracts in the study, we analyzed the genome-wide 
transcriptional response in the context of known functional activities and interrelationships 
among specific protein molecules and/or different cell phenotypes. Ingenuity systems, a 
structured network knowledge-based approach, provided us good tools and insight into the 
regulation of bone marrow-derived dendritic cell activities relevant to the body’s immune 
system. Figure 5 shows candidate molecular networks revealed by clustering analysis of the 
representative genes involved in the BMDC response to [BF/S+L/Ep] treatment [17]. The 
prototypical cell was constructed from 37 representative genes that responded to treatment 
with [BF/S+L/Ep] in vitro from 4 hours to 12 hours. Genes whose expression was upregulated 
(more than doubled) are indicated in red, and those whose expression was downregulated (to 
less than half) are shown in green. Selected regions of the network highlight three groups of 
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genes. Group 1: Immune response-related genes. Group 2: Adhesion molecules and 
cytoskeleton; cell movement related genes. Group 3: Cell cycle, cell proliferation and apoptosis 
related genes. Gene networks were analyzed using the Ingenuity Pathways program. 
 
 
Fig. 5. Pathway analysis of representative genes that responded to [BF/S+L/Ep] treatment [17].  
5.2 Metacore™ (http://www.genego.com/metacore.php) 
MetaCore™ is another integrated knowledge database and software suite for pathway 
analysis of experimental data and gene lists. In the research of phytomedicines, it has  
also been used to evaluate the possible hierarchical control of microRNA expression from 
mouse tissues in order to identify trends of miRNA and mRNA expressions in response to 
targeted phytomedicinal treatment. Utilizing Metacore software, a prototypical network 
was constructed from 6 representative microRNAs that responded to treatment in vivo  
with specific phyto-chemicals (Figure 6). All selected microRNAs were found to be  
down-regulated to less than half of the untreated levels, and are shown with blue circles.  
 
 
Fig. 6. Pathway/network analysis of representative microRNAs which are responsive in vivo 
to a specific single phytocompound treatment in inflammed mouse tissues. 
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Specifically, connections (hits) within 6 microRNAs were employed as the parameter for this 
specific search. Arrows indicate the cross talks among five key molecules/pathways, (TCF8, 
VEGF-A, FOG2, MIG6, SIP1 and WASF3), and there are postulated to be regulated by 
treatment with a specific phyto-chemical from TCM formulation. 
5.3 TRANTHPATH (http://www.gene-regulation.com/index.html) 
TRANSPATH, a database system about gene regulatory networks, combines encyclopedic 
information on signal transduction with tools for visualization and analysis. By integrating 
with TRANSFAC, a database about transcription factors and their DNA binding sites, 
TRANSPATH can predict putative signaling pathways from ligand to target genes and their 
products, which may themselves be involved in a regulatory action. 
For studying specific imumodulatory effect of herbal medicine, the possible signaling 
pathways, networks or potential interactions among the responsive genes/target molecules in 
DCs treated with Echinacea extracts [BF/S+L/Ep] was assessed by using such Transpath 
software. This bioinformatics analysis has predicted a key-signaling network involving a 
number of immune-modulatory molecules leading to the activation of a very important 
downstream regulatory molecule, the adenylate cyclase 8, effectively in regulating cAMP 
levels in mammalian cells. This analysis indicated two postulated key molecules/pathways, 
Adenylate cyclase (AC8) and calmudulin (CaM), responsive to the Echinacea extracts (Figure 7). 
 
 
 
Fig. 7. Bioinformatics analysis of [BF/S+L/Ep] bioactivity and the underlying candidate 
molecular signaling networks in human DCs. The 20 genes that were up- or down-regulated 
at least 5-fold over controls were analyzed. Specifically, connections (hits) within 7 genes 
were employed as the parameter for the current search [63].  
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5.4 KEGG (http://www.kegg.jp/kegg/) 
KEGG (Kyoto Encyclopedia of Genes and Genomes) is a multi-functional bioinformatics resource 
for linking genomes to metabolic activities. It consists of 16 main databases and has been 
widely used as a reference knowledge base for biological interpretation of large-scale datasets 
generated by sequencing and other high-throughput experimental technologies. Among these 
databases, the KEGG DRUG database contains crude drugs (consisting of multiple chemical 
compounds) and formulas (consisting of multiple crude drugs) in the Traditional Chinese 
Medicine (TCM). In addition, KEGG PATHWAY and KEGG ENVIRON are also being 
organized to interpret and correlate relationships between genomic and chemical information 
of various natural products/metabolites from plants. For example, the biosynthetic pathway 
of stilbenoids, a group of phenolic compounds, was provided for revealing specific molecular 
interaction and different reaction networks (Figure 8). Although the knowledge on 
biosynthetic pathways of plant natural products is in general largely incomplete, the genomic 
information is expected to provide clues to missing enzymes and reactions for biosynthesis of 
specific plant secondary metabolites, the source for future modernized phytomedicines, either 
as pure compounds, fractionated phytochemical mixtures, or as crude plant extracts. 
Moreover, the genomic information may also uncover the architecture of biosynthetic 
pathways for generating chemical diversity of natural products. 
 
 
Fig. 8. Stilbenoid, diarylheptanoid and gingerol biosynthetic networks cited in KEGG. 
(Adopted from http://www.kegg.jp/kegg/pathway/map/map00945.html) 
6. Challenges and perspectives 
Traditionally, the pharmaceutical research and industries have focused on evaluating or 
monitoring individual gene, proteins as the target or basis for identifying new drugs. The 
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quest for single molecules to modify single key factors in a disease process is now 
recognized as may not be able to provide a solution for a spectrum of diseases in which 
multiple cell types, target molecules and/or multiple pathways are known or believed to 
contribute to the diseases. Herbal extracts/mixtures as conventional phytomedicines may 
represent the combinational chemistry of the nature of traditional medicines, and 
encompass a vast repertoire of chemical entities that may have anecdotally and empirically 
found through long human culture history to confer a complex and yet integrated effect on 
numerous cellular components and functions, effecting a medicinal activity. Various 
traditional herbal drugs may thus have good potential for re-invention and newly found use 
in the multi-target approach in treating various diseases. However, such potential of herbal 
drugs is undermined by difficulties in standardization, and the pharmacodynamics and 
pharmacokinetics studies of these multicomponent plant extract mixtures. Microarray 
analysis of gene expression profiles may be useful for elucidating such complex molecular 
mechanisms and networks underlying the multi-target pharmacological functions of herbal 
extracts and phytomedicine mixtures. Research into the patterns of gene expression at a 
range of stages during the treatment process may reveal key targets and mechanisms and 
help to identify biomarkers of either adverse- or favorable response. A positive correlation 
between the transcriptional response induced by a putative or candidate herbal drug and 
the database profile of an existing pharmaceutical or therapeutic agent as a single chemical 
may provide us insight into the target specificity, mechanism of action, as well as in 
facilitating analysis of signaling pathways downstream of the specific target. This 
information could in turn be used to interpret possible bioactivity, function or effectiveness 
of test phytomedicines. In addition, various DNA, RNA or protein microarrays may also be 
used for bioactivity-guided fractionation of herbal extracts, thereby narrowing in the active 
principles delivering the desired or observed effect. Microarrays may also improve the 
power for selection of biological targets and lead compounds up or down the drug 
discovery pipeline. Once useful transcriptome or/and proteome data from herbal drug 
candidates can be correlated with in vivo bioactivity or preclinical or “existing clinical” (as in 
some TCM) response outcomes (biomarkers) in defined biological systems, the best 
candidates can then be selected for further drug development [30].  
Although some DNA microarrays have already offered impressive potential for 
pharmacodynamics and toxigenomics applications, they are still being considered as in an 
exploratory stage and the data obtained from them will need validation by other biological 
experiments. Bioinformatics and statistical tools have a major role to play in analysis of the 
microarray results, whereby data from multiple experiments can and may need to be 
integrated to address complex biological activities, functions or effects. Another factor 
currently limiting microarray application is the cost of this technology [30]. The challenge 
we face today is to develop or construct standardized, sensitive, reproducible microarray 
platforms, databases and visualization methods for expression profiles that are affordable to 
most research scientists. With the use or development of improved, uniform and 
sophisticated experimental designs, data management systems [126, 127], statistical tools 
and upgraded algorithms for data analysis [128, 129], DNA microarrays hopefully can be 
more optimally used in herbal drug research. In spite of the vast potential offered by 
microarray and the related functional genomics and proteomics technology, the importance 
of integrating various in vitro biological assays, cell culture-based and in vivo animal 
experimental systems cannot be ignored. Comprehensive strategy integrating information 
from diverse scientific experiments and technologies are expected to benefit and lead to 
molecule and cell evidence-based phytomedicines. 
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The integration of information from genomics, proteomics, and metabolomics is hoped to 
provide solid evidence-based rationales for systematic development of various modern 
phytomedicines, on top of the foundations of various traditional medicine cultures. The 
search for specific, active single phytocompound may also be expedited when various 
metabolomics approaches are combined with a comprehensive array of bioactivity assay 
systems using standardized and normalizable mammalian cell, tissue and animal models. 
Wherea a “complete metabolome-exhibition” system is currently not available, HPLC-, GC- 
and LC/MS-based metabolite-profiling systems, alone or in combination, may already offer 
a good description or authentication tool for comparative and qualitative analyses and 
definition of the unique, distinctive, or combinational profile features of the conventional 
herbal medicine formulations, as elegantly demonstrated recently by W. Lam et al (2010) 
[112]. These and the improved or newly developed metabolomics technologies in linkage 
may also be usefully applied to discovery and development of new phytomedicines, as 
single phyto-chemicals or their mixtures, or as fractions or the whole preparation of the 
crude extracts of various medicinal plant tissues. Our challenges together, as scientists and 
health care-takers are to coordinate and integrate our intellectual thrusts, talents and efforts 
to address and target specific medical and medicinal research areas, e.g., for anti-
inflammation and related chronic or cancerous diseases, for future research and 
development of advanced phytomedicines, may be to be pursued more effectively as an 
international program. 
7. References 
[1] E. Fridman, E. Pichersky, Metabolomics, genomics, proteomics, and the identification of 
enzymes and their substrates and products, Curr Opin Plant Biol 8 (2005) 242-248. 
[2] D.J. Lockhart, H. Dong, M.C. Byrne, M.T. Follettie, M.V. Gallo, M.S. Chee, M. Mittmann, 
C. Wang, M. Kobayashi, H. Horton, E.L. Brown, Expression monitoring by 
hybridization to high-density oligonucleotide arrays, Nat Biotechnol 14 (1996) 1675-
1680. 
[3] A. Pandey, M. Mann, Proteomics to study genes and genomes, Nature 405 (2000) 837-
846. 
[4] L. Lederman, Bioinformatics and systems biology, Biotechniques 46 (2009) 501-503. 
[5] Y.L. Yip, The promise of systems biology in clinical applications. Findings from the 
Yearbook 2008 Section on Bioinformatics, Yearb Med Inform (2008) 102-104. 
[6] F.A. Middleton, C. Rosenow, A. Vailaya, A. Kuchinsky, M.T. Pato, C.N. Pato, Integrating 
genetic, functional genomic, and bioinformatics data in a systems biology approach 
to complex diseases: application to schizophrenia, Methods Mol Biol 401 (2007) 337-
364. 
[7] N. Rapin, C. Kesmir, S. Frankild, M. Nielsen, C. Lundegaard, S. Brunak, O. Lund, 
Modelling the human immune system by combining bioinformatics and systems 
biology approaches, J Biol Phys 32 (2006) 335-353. 
[8] T. Yao, Bioinformatics for the genomic sciences and towards systems biology. Japanese 
activities in the post-genome era, Prog Biophys Mol Biol 80 (2002) 23-42. 
[9] L.B. Ray, L.D. Chong, N.R. Gough, Computational biology, Sci STKE 2002 (2002) eg10. 
[10] J.J. Hutton, A.G. Jegga, S. Kong, A. Gupta, C. Ebert, S. Williams, J.D. Katz, B.J. Aronow, 
Microarray and comparative genomics-based identification of genes and gene 
regulatory regions of the mouse immune system, BMC Genomics 5 (2004) 82. 
www.intechopen.com
 
Immuno-Modulatory Effects of Phytomedicines Evaluated Using Omics Approaches 
 
307 
[11] L.M. Staudt, P.O. Brown, Genomic views of the immune system*, Annu Rev Immunol 
18 (2000) 829-859. 
[12] N.J. Davies, M.G. Tadesse, M. Vannucci, H. Kikuchi, V. Trevino, D. Sarti, I. Dragoni, A. 
Contestabile, E. Zanders, F. Falciani, Making sense of molecular signatures in the 
immune system, Comb Chem High Throughput Screen 7 (2004) 231-238. 
[13] L.A. Burns-Naas, R.J. Dearman, D.R. Germolec, N.E. Kaminski, I. Kimber, G.S. Ladics, 
R.W. Luebke, J.C. Pfau, S.B. Pruett, "Omics" Technologies and the Immune System 
(a) , (b), Toxicol Mech Methods 16 (2006) 101-119. 
[14] S.D. Holladay, L.V. Sharova, K. Punareewattana, T.C. Hrubec, R.M. Gogal, Jr., M.R. 
Prater, A.A. Sharov, Maternal immune stimulation in mice decreases fetal 
malformations caused by teratogens, Int Immunopharmacol 2 (2002) 325-332. 
[15] S. Kinser, Q. Jia, M. Li, A. Laughter, P. Cornwell, J.C. Corton, J. Pestka, Gene expression 
profiling in spleens of deoxynivalenol-exposed mice: immediate early genes as 
primary targets, J Toxicol Environ Health A 67 (2004) 1423-1441. 
[16] M.T. Fisher, M. Nagarkatti, P.S. Nagarkatti, Combined screening of thymocytes using 
apoptosis-specific cDNA array and promoter analysis yields novel gene targets 
mediating TCDD-induced toxicity, Toxicol Sci 78 (2004) 116-124. 
[17] S.Y. Yin, W.H. Wang, B.X. Wang, K. Aravindaram, P.I. Hwang, H.M. Wu, N.S. Yang, 
Stimulatory effect of Echinacea purpurea extract on the trafficking activity of 
mouse dendritic cells: revealed by genomic and proteomic analyses, BMC 
Genomics 11 612. 
[18] M. Swindells, M. Rae, M. Pearce, S. Moodie, R. Miller, P. Leach, Application of high-
throughput computing in bioinformatics, Philos Transact A Math Phys Eng Sci 360 
(2002) 1179-1189. 
[19] M.G. Kann, Advances in translational bioinformatics: computational approaches for the 
hunting of disease genes, Brief Bioinform 11 96-110. 
[20] M. Wang, R.J. Lamers, H.A. Korthout, J.H. van Nesselrooij, R.F. Witkamp, R. van der 
Heijden, P.J. Voshol, L.M. Havekes, R. Verpoorte, J. van der Greef, Metabolomics in 
the context of systems biology: bridging traditional Chinese medicine and 
molecular pharmacology, Phytother Res 19 (2005) 173-182. 
[21] W.C. Cho, Application of proteomics in Chinese medicine research, Am J Chin Med 35 
(2007) 911-922. 
[22] R.J. Lamers, J. DeGroot, E.J. Spies-Faber, R.H. Jellema, V.B. Kraus, N. Verzijl, J.M. 
TeKoppele, G.K. Spijksma, J.T. Vogels, J. van der Greef, J.H. van Nesselrooij, 
Identification of disease- and nutrient-related metabolic fingerprints in 
osteoarthritic Guinea pigs, J Nutr 133 (2003) 1776-1780. 
[23] B.A. t Hart, J.T. Vogels, G. Spijksma, H.P. Brok, C. Polman, J. van der Greef, 1H-NMR 
spectroscopy combined with pattern recognition analysis reveals characteristic 
chemical patterns in urines of MS patients and non-human primates with MS-like 
disease, J Neurol Sci 212 (2003) 21-30. 
[24] L.F. Shyur, N.S. Yang, Metabolomics for phytomedicine research and drug 
development, Curr Opin Chem Biol 12 (2008) 66-71. 
[25] V.V. Barnatskii, V.D. Grigor'eva, S.B. Pershin, N.A. Derevnina, E.B. Gontar, [Influence 
of combined rehabilitation treatment including novel non-pharmacological 
technologies on immune system of patients with seronegetive spondylarthritis], 
Vopr Kurortol Fizioter Lech Fiz Kult (2005) 20-24. 
www.intechopen.com
 
Systems and Computational Biology – Molecular and Cellular Experimental Systems 
 
308 
[26] J. Ezendam, F. Staedtler, J. Pennings, R.J. Vandebriel, R. Pieters, J.H. Harleman, J.G. Vos, 
Toxicogenomics of subchronic hexachlorobenzene exposure in Brown Norway rats, 
Environ Health Perspect 112 (2004) 782-791. 
[27] M.J. Rhile, M. Nagarkatti, P.S. Nagarkatti, Role of Fas apoptosis and MHC genes in 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced immunotoxicity of T cells, 
Toxicology 110 (1996) 153-167. 
[28] I.A. Camacho, N. Singh, V.L. Hegde, M. Nagarkatti, P.S. Nagarkatti, Treatment of mice 
with 2,3,7,8-tetrachlorodibenzo-p-dioxin leads to aryl hydrocarbon receptor-
dependent nuclear translocation of NF-kappaB and expression of Fas ligand in 
thymic stromal cells and consequent apoptosis in T cells, J Immunol 175 (2005) 90-
103. 
[29] C.G. Wermuth, Multitargeted drugs: the end of the "one-target-one-disease" 
philosophy?, Drug Discov Today 9 (2004) 826-827. 
[30] P. Chavan, K. Joshi, B. Patwardhan, DNA microarrays in herbal drug research, Evid 
Based Complement Alternat Med 3 (2006) 447-457. 
[31] S. Amagaya, A. Iizuka, B. Makino, M. Kubo, Y. Komatsu, F.C. Cheng, T.I. Ruo, T. Itoh, 
K. Terasawa, General pharmacological properties of Sho-seiryu-to (TJ-19) extracts, 
Phytomedicine 8 (2001) 338-347. 
[32] K.K. Ahmed, A.C. Rana, V.K. Dixit, B.G. Shivananda, Internet--implications for the 
future of phytopharmacological research, Indian J Exp Biol 41 (2003) 1233-1238. 
[33] S. Katz, R. Harris, J.T. Lau, A. Chau, The use of gene expression analysis and proteomic 
databases in the development of a screening system to determine the value of 
natural medicinal products, Evid Based Complement Alternat Med 3 (2006) 65-70. 
[34] J.P. Luyendyk, W.B. Mattes, L.D. Burgoon, T.R. Zacharewski, J.F. Maddox, G.N. Cosma, 
P.E. Ganey, R.A. Roth, Gene expression analysis points to hemostasis in livers of 
rats cotreated with lipopolysaccharide and ranitidine, Toxicol Sci 80 (2004) 203-213. 
[35] S.B. Pruett, C. Schwab, Q. Zheng, R. Fan, Suppression of innate immunity by acute 
ethanol administration: a global perspective and a new mechanism beginning with 
inhibition of signaling through TLR3, J Immunol 173 (2004) 2715-2724. 
[36] P. Mondola, F. Santangelo, C. Falconi, A. Belfiore, The serum apo B and apo E in rats 
following cholesterol diet and thymus treatment, Horm Metab Res 19 (1987) 407-
410. 
[37] P.A. Clarke, R. te Poele, R. Wooster, P. Workman, Gene expression microarray analysis 
in cancer biology, pharmacology, and drug development: progress and potential, 
Biochem Pharmacol 62 (2001) 1311-1336. 
[38] D.J. Crowther, Applications of microarrays in the pharmaceutical industry, Curr Opin 
Pharmacol 2 (2002) 551-554. 
[39] M.I. Klapa, J. Quackenbush, The quest for the mechanisms of life, Biotechnol Bioeng 84 
(2003) 739-742. 
[40] W.J. Zhuang, C.C. Fong, J. Cao, L. Ao, C.H. Leung, H.Y. Cheung, P.G. Xiao, W.F. Fong, 
M.S. Yang, Involvement of NF-kappaB and c-myc signaling pathways in the 
apoptosis of HL-60 cells induced by alkaloids of Tripterygium hypoglaucum (levl.) 
Hutch, Phytomedicine 11 (2004) 295-302. 
[41] Y. Chen, Z.Y. Shen, W.H. Chen, [Molecular mechanism of epimedium flavonoids in 
immune homeostasis remodeling in aged rats revealed by lymphocyte gene 
expression profile], Zhongguo Zhong Xi Yi Jie He Za Zhi 24 (2004) 59-62. 
www.intechopen.com
 
Immuno-Modulatory Effects of Phytomedicines Evaluated Using Omics Approaches 
 
309 
[42] C.Q. Hu, X.G. Chen, C.M. Li, G.J. Chen, Q. Zhao, Effect of "Si Jun Zi (four gentlemen) 
Tang" decoction on monoamine transmitter in brain of reserpinized mice, J Tradit 
Chin Med 3 (1983) 33-35. 
[43] L. Liu, L. Han, D.Y. Wong, P.Y. Yue, W.Y. Ha, Y.H. Hu, P.X. Wang, R.N. Wong, Effects 
of Si-Jun-Zi decoction polysaccharides on cell migration and gene expression in 
wounded rat intestinal epithelial cells, Br J Nutr 93 (2005) 21-29. 
[44] X. Chen, L. Yang, J.J. Oppenheim, M.Z. Howard, Cellular pharmacology studies of 
shikonin derivatives, Phytother Res 16 (2002) 199-209. 
[45] K. Nakaya, T. Miyasaka, A shikonin derivative, beta-hydroxyisovalerylshikonin, is an 
ATP-non-competitive inhibitor of protein tyrosine kinases, Anticancer Drugs 14 
(2003) 683-693. 
[46] V. Staniforth, S.Y. Wang, L.F. Shyur, N.S. Yang, Shikonins, phytocompounds from 
Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor 
necrosis factor alpha promoter in vivo, J Biol Chem 279 (2004) 5877-5885. 
[47] S.C. Chiu, N.S. Yang, Inhibition of tumor necrosis factor-alpha through selective 
blockade of Pre-mRNA splicing by shikonin, Mol Pharmacol 71 (2007) 1640-1645. 
[48] S.C. Chiu, S.W. Tsao, P.I. Hwang, S. Vanisree, Y.A. Chen, N.S. Yang, Differential 
functional genomic effects of anti-inflammatory phytocompounds on immune 
signaling, BMC Genomics 11 513. 
[49] S. Roy, S. Khanna, H. Shah, C. Rink, C. Phillips, H. Preuss, G.V. Subbaraju, G. 
Trimurtulu, A.V. Krishnaraju, M. Bagchi, D. Bagchi, C.K. Sen, Human genome 
screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in 
microvascular endothelial cells, DNA Cell Biol 24 (2005) 244-255. 
[50] G.B. Singh, C.K. Atal, Pharmacology of an extract of salai guggal ex-Boswellia serrata, a 
new non-steroidal anti-inflammatory agent, Agents Actions 18 (1986) 407-412. 
[51] N. Nakamura, [Antigen presentation and immune induction by dendritic cells], 
Tanpakushitsu Kakusan Koso 53 (2008) 2263-2268. 
[52] Y. Jin, L. Fuller, G. Ciancio, G.W. Burke, 3rd, A.G. Tzakis, C. Ricordi, J. Miller, V. 
Esquenzai, Antigen presentation and immune regulatory capacity of immature and 
mature-enriched antigen presenting (dendritic) cells derived from human bone 
marrow, Hum Immunol 65 (2004) 93-103. 
[53] U. Yrlid, M. Svensson, C. Johansson, M.J. Wick, Salmonella infection of bone marrow-
derived macrophages and dendritic cells: influence on antigen presentation and 
initiating an immune response, FEMS Immunol Med Microbiol 27 (2000) 313-320. 
[54] P.R. Bergstresser, G.B. Toews, J.W. Streilein, Natural and perturbed distributions of 
Langerhans cells: responses to ultraviolet light, heterotopic skin grafting, and 
dinitrofluorobenzene sensitization, J Invest Dermatol 75 (1980) 73-77. 
[55] M. Cumberbatch, J.C. Hope, R.J. Dearman, S.J. Hopkins, I. Kimber, Migration of 
interleukin-6 producing Langerhans cells to draining lymph nodes following skin 
sensitization, Adv Exp Med Biol 378 (1995) 531-533. 
[56] A.H. Enk, S.I. Katz, Early molecular events in the induction phase of contact sensitivity, 
Proc Natl Acad Sci U S A 89 (1992) 1398-1402. 
[57] G.M. Halliday, H.K. Muller, Sensitization through carcinogen-induced Langerhans cell-
deficient skin activates specific long-lived suppressor cells for both cellular and 
humoral immunity, Cell Immunol 109 (1987) 206-221. 
www.intechopen.com
 
Systems and Computational Biology – Molecular and Cellular Experimental Systems 
 
310 
[58] I. Kimber, M. Cumberbatch, Dendritic cells and cutaneous immune responses to 
chemical allergens, Toxicol Appl Pharmacol 117 (1992) 137-146. 
[59] I. Kimber, M. Cumberbatch, R.J. Dearman, M. Bhushan, C.E. Griffiths, Cytokines and 
chemokines in the initiation and regulation of epidermal Langerhans cell 
mobilization, Br J Dermatol 142 (2000) 401-412. 
[60] S. Casati, P. Aeby, D.A. Basketter, A. Cavani, A. Gennari, G.F. Gerberick, P. Griem, T. 
Hartung, I. Kimber, J.P. Lepoittevin, B.J. Meade, M. Pallardy, N. Rougier, F. 
Rousset, G. Rubinstenn, F. Sallusto, G.R. Verheyen, V. Zuang, Dendritic cells as a 
tool for the predictive identification of skin sensitisation hazard, Altern Lab Anim 
33 (2005) 47-62. 
[61] W.D. Pennie, I. Kimber, Toxicogenomics; transcript profiling and potential application 
to chemical allergy, Toxicol In Vitro 16 (2002) 319-326. 
[62] C.A. Ryan, G.F. Gerberick, L.A. Gildea, B.C. Hulette, C.J. Betts, M. Cumberbatch, R.J. 
Dearman, I. Kimber, Interactions of contact allergens with dendritic cells: 
opportunities and challenges for the development of novel approaches to hazard 
assessment, Toxicol Sci 88 (2005) 4-11. 
[63] C.Y. Wang, V. Staniforth, M.T. Chiao, C.C. Hou, H.M. Wu, K.C. Yeh, C.H. Chen, P.I. 
Hwang, T.N. Wen, L.F. Shyur, N.S. Yang, Genomics and proteomics of immune 
modulatory effects of a butanol fraction of echinacea purpurea in human dendritic 
cells, BMC Genomics 9 (2008) 479. 
[64] C.Y. Wang, M.T. Chiao, P.J. Yen, W.C. Huang, C.C. Hou, S.C. Chien, K.C. Yeh, W.C. 
Yang, L.F. Shyur, N.S. Yang, Modulatory effects of Echinacea purpurea extracts on 
human dendritic cells: a cell- and gene-based study, Genomics 88 (2006) 801-808. 
[65] M. Carles, M.K. Cheung, S. Moganti, T.T. Dong, K.W. Tsim, N.Y. Ip, N.J. Sucher, A 
DNA microarray for the authentication of toxic traditional Chinese medicinal 
plants, Planta Med 71 (2005) 580-584. 
[66] K.L. Wan, J.M. Blackwell, J.W. Ajioka, Toxoplasma gondii expressed sequence tags: 
insight into tachyzoite gene expression, Mol Biochem Parasitol 75 (1996) 179-186. 
[67] J. Liu, C. Hara, M. Umeda, Y. Zhao, T.W. Okita, H. Uchimiya, Analysis of randomly 
isolated cDNAs from developing endosperm of rice (Oryza sativa L.): evaluation of 
expressed sequence tags, and expression levels of mRNAs, Plant Mol Biol 29 (1995) 
685-689. 
[68] S.L. Chen, Y.Q. Sun, J.Y. Song, Y. Li, C.J. Li, S.N. Hu, X.W. Li, H. Yao, X.W. Zhang, 
[Analysis of expressed sequence tags (EST) from Panax quinquefolium root], Yao 
Xue Xue Bao 43 (2008) 657-663. 
[69] H. Luo, C. Sun, Y. Li, Q. Wu, J. Song, D. Wang, X. Jia, R. Li, S. Chen, Analysis of 
expressed sequence tags from the Huperzia serrata leaf for gene discovery in the 
areas of secondary metabolite biosynthesis and development regulation, Physiol 
Plant 139 1-12. 
[70] F. He, Y. Zhu, Y. Zhang, Identification and characterization of differentially expressed 
genes involved in pharmacological activities of roots of Panax notoginseng during 
plant growth, Plant Cell Rep 27 (2008) 923-930. 
[71] P. Sun, Y. Guo, J. Qi, L. Zhou, X. Li, Isolation and expression analysis of tuberous root 
development related genes in Rehmannia glutinosa, Mol Biol Rep 37 1069-1079. 
www.intechopen.com
 
Immuno-Modulatory Effects of Phytomedicines Evaluated Using Omics Approaches 
 
311 
[72] A.K. Shukla, A.K. Shasany, M.M. Gupta, S.P. Khanuja, Transcriptome analysis in 
Catharanthus roseus leaves and roots for comparative terpenoid indole alkaloid 
profiles, J Exp Bot 57 (2006) 3921-3932. 
[73] Y. Deng, Y. Dong, V. Thodima, R.J. Clem, A.L. Passarelli, Analysis and functional 
annotation of expressed sequence tags from the fall armyworm Spodoptera 
frugiperda, BMC Genomics 7 (2006) 264. 
[74] V.K. Thara, A.R. Seilaniantz, Y. Deng, Y. Dong, Y. Yang, X. Tang, J.M. Zhou, Tobacco 
genes induced by the bacterial effector protein AvrPto, Mol Plant Microbe Interact 
17 (2004) 1139-1145. 
[75] E.V. Boyko, C.M. Smith, V.K. Thara, J.M. Bruno, Y. Deng, S.R. Starkey, D.L. Klaahsen, 
Molecular basis of plant gene expression during aphid invasion: wheat Pto- and 
Pti-like sequences are involved in interactions between wheat and Russian wheat 
aphid (Homoptera: Aphididae), J Econ Entomol 99 (2006) 1430-1445. 
[76] W.C. Cho, Contribution of oncoproteomics to cancer biomarker discovery, Mol Cancer 6 
(2007) 25. 
[77] W.C. Cho, C.H. Cheng, Oncoproteomics: current trends and future perspectives, Expert 
Rev Proteomics 4 (2007) 401-410. 
[78] P.H. O'Farrell, High resolution two-dimensional electrophoresis of proteins, J Biol 
Chem 250 (1975) 4007-4021. 
[79] J. Klose, Protein mapping by combined isoelectric focusing and electrophoresis of 
mouse tissues. A novel approach to testing for induced point mutations in 
mammals, Humangenetik 26 (1975) 231-243. 
[80] S.A. Smith, T.A. Blake, D.R. Ifa, R.G. Cooks, Z. Ouyang, Dual-source mass spectrometer 
with MALDI-LIT-ESI configuration, J Proteome Res 6 (2007) 837-845. 
[81] L.H. Cazares, B.L. Adam, M.D. Ward, S. Nasim, P.F. Schellhammer, O.J. Semmes, G.L. 
Wright, Jr., Normal, benign, preneoplastic, and malignant prostate cells have 
distinct protein expression profiles resolved by surface enhanced laser 
desorption/ionization mass spectrometry, Clin Cancer Res 8 (2002) 2541-2552. 
[82] M. Gao, C. Deng, S. Lin, F. Hu, J. Tang, N. Yao, X. Zhang, Recent developments and 
contributions from Chinese scientists in multidimensional separations for 
proteomics and traditional Chinese medicines, J Sep Sci 30 (2007) 785-791. 
[83] J.K. Wen, M. Han, [Application of genomics and proteomics in study of traditional 
Chinese medicine], Zhong Xi Yi Jie He Xue Bao 2 (2004) 323-325. 
[84] J.H. Lum, K.L. Fung, P.Y. Cheung, M.S. Wong, C.H. Lee, F.S. Kwok, M.C. Leung, P.K. 
Hui, S.C. Lo, Proteome of Oriental ginseng Panax ginseng C. A. Meyer and the 
potential to use it as an identification tool, Proteomics 2 (2002) 1123-1130. 
[85] W.C. Cho, K.N. Leung, In vitro and in vivo anti-tumor effects of Astragalus 
membranaceus, Cancer Lett 252 (2007) 43-54. 
[86] W.C. Cho, K.N. Leung, In vitro and in vivo immunomodulating and immunorestorative 
effects of Astragalus membranaceus, J Ethnopharmacol 113 (2007) 132-141. 
[87] H.N. Koo, H.J. Jeong, I.Y. Choi, H.J. An, P.D. Moon, S.J. Kim, S.Y. Jee, J.Y. Um, S.H. 
Hong, S.S. Shin, D.C. Yang, Y.S. Seo, H.M. Kim, Mountain grown ginseng induces 
apoptosis in HL-60 cells and its mechanism have little relation with TNF-alpha 
production, Am J Chin Med 35 (2007) 169-182. 
www.intechopen.com
 
Systems and Computational Biology – Molecular and Cellular Experimental Systems 
 
312 
[88] M.J. Liu, Z. Wang, Y. Ju, J.B. Zhou, Y. Wang, R.N. Wong, The mitotic-arresting and 
apoptosis-inducing effects of diosgenyl saponins on human leukemia cell lines, Biol 
Pharm Bull 27 (2004) 1059-1065. 
[89] Y. Wang, Y.H. Cheung, Z. Yang, J.F. Chiu, C.M. Che, Q.Y. He, Proteomic approach to 
study the cytotoxicity of dioscin (saponin), Proteomics 6 (2006) 2422-2432. 
[90] W.C. Cho, [Research progress in SELDI-TOF MS and its clinical applications], Sheng 
Wu Gong Cheng Xue Bao 22 (2006) 871-876. 
[91] B, Linda, Metabolomics: working toward personalized medicine, FDA Consum 
39(2005)28-33. 
[92] O. Fiehn, J. Kopka, P. Dormann, T. Altmann, R.N. Trethewey, L. Willmitzer, Metabolite 
profiling for plant functional genomics, Nat Biotechnol 18 (2000) 1157-1161. 
[92] U.M. Malyankar, Tumor-associated antigens and biomarkers in cancer and immune 
therapy, Int Rev Immunol 26 (2007) 223-247. 
[94] L.W. Sumner, P. Mendes, R.A. Dixon, Plant metabolomics: large-scale phytochemistry 
in the functional genomics era, Phytochemistry 62 (2003) 817-836. 
[95] R. t'Kindt, K. Morreel, D. Deforce, W. Boerjan, J. Van Bocxlaer, Joint GC-MS and LC-MS 
platforms for comprehensive plant metabolomics: repeatability and sample pre-
treatment, J Chromatogr B Analyt Technol Biomed Life Sci 877 (2009) 3572-3580. 
[96] Z.D. Zeng, Y.Z. Liang, F.T. Chau, S. Chen, M.K. Daniel, C.O. Chan, Mass spectral 
profiling: an effective tool for quality control of herbal medicines, Anal Chim Acta 
604 (2007) 89-98. 
[97] S.Y. Yang, H.K. Kim, A.W. Lefeber, C. Erkelens, N. Angelova, Y.H. Choi, R. Verpoorte, 
Application of two-dimensional nuclear magnetic resonance spectroscopy to 
quality control of ginseng commercial products, Planta Med 72 (2006) 364-369. 
[98] H.H. Draisma, T.H. Reijmers, F. van der Kloet, I. Bobeldijk-Pastorova, E. Spies-Faber, 
J.T. Vogels, J.J. Meulman, D.I. Boomsma, J. van der Greef, T. Hankemeier, Equating, 
or correction for between-block effects with application to body fluid LC-MS and 
NMR metabolomics data sets, Anal Chem 82 1039-1046. 
[99] B. Biais, J.W. Allwood, C. Deborde, Y. Xu, M. Maucourt, B. Beauvoit, W.B. Dunn, D. 
Jacob, R. Goodacre, D. Rolin, A. Moing, 1H NMR, GC-EI-TOFMS, and data set 
correlation for fruit metabolomics: application to spatial metabolite analysis in 
melon, Anal Chem 81 (2009) 2884-2894. 
[100] N.J. Serkova, J.L. Spratlin, S.G. Eckhardt, NMR-based metabolomics: translational 
application and treatment of cancer, Curr Opin Mol Ther 9 (2007) 572-585. 
[101] E.C. Horning, M.G. Horning, Metabolic profiles: gas-phase methods for analysis of 
metabolites, Clin Chem 17 (1971) 802-809. 
[102] L. Pauling, A.B. Robinson, R. Teranishi, P. Cary, Quantitative analysis of urine vapor 
and breath by gas-liquid partition chromatography, Proc Natl Acad Sci U S A 68 
(1971) 2374-2376. 
[103] M. Kusano, A. Fukushima, M. Kobayashi, N. Hayashi, P. Jonsson, T. Moritz, K. Ebana, 
K. Saito, Application of a metabolomic method combining one-dimensional and 
two-dimensional gas chromatography-time-of-flight/mass spectrometry to 
metabolic phenotyping of natural variants in rice, J Chromatogr B Analyt Technol 
Biomed Life Sci 855 (2007) 71-79. 
www.intechopen.com
 
Immuno-Modulatory Effects of Phytomedicines Evaluated Using Omics Approaches 
 
313 
[104] G. Sun, K. Yang, Z. Zhao, S. Guan, X. Han, R.W. Gross, Shotgun metabolomics 
approach for the analysis of negatively charged water-soluble cellular metabolites 
from mouse heart tissue, Anal Chem 79 (2007) 6629-6640. 
[105] J.C. Lindon, E. Holmes, J.K. Nicholson, Metabonomics in pharmaceutical R&D, FEBS J 
274 (2007) 1140-1151. 
[106] I.A. Lewis, S.C. Schommer, B. Hodis, K.A. Robb, M. Tonelli, W.M. Westler, M.R. 
Sussman, J.L. Markley, Method for determining molar concentrations of 
metabolites in complex solutions from two-dimensional 1H-13C NMR spectra, 
Anal Chem 79 (2007) 9385-9390. 
[107] M. Lambert, J.L. Wolfender, D. Staerk, S.B. Christensen, K. Hostettmann, J.W. 
Jaroszewski, Identification of natural products using HPLC-SPE combined with 
CapNMR, Anal Chem 79 (2007) 727-735. 
[108] C. Clarkson, D. Staerk, S.H. Hansen, P.J. Smith, J.W. Jaroszewski, Discovering new 
natural products directly from crude extracts by HPLC-SPE-NMR: chinane 
diterpenes in Harpagophytum procumbens, J Nat Prod 69 (2006) 527-530. 
[109] N. Schauer, A.R. Fernie, Plant metabolomics: towards biological function and 
mechanism, Trends Plant Sci 11 (2006) 508-516. 
[110] B. Singh, T.K. Bhat, Potential therapeutic applications of some antinutritional plant 
secondary metabolites, J Agric Food Chem 51 (2003) 5579-5597. 
[111] D.J. Newman, G.M. Cragg, Natural products as sources of new drugs over the last 25 
years, J Nat Prod 70 (2007) 461-477. 
[112] E.M. Williamson, Synergy and other interactions in phytomedicines, Phytomedicine 8 
(2001) 401-409. 
[113] W. Lam, S. Bussom, F. Guan, Z. Jiang, W. Zhang, E.A. Gullen, S.H. Liu, Y.C. Cheng, 
The four-herb Chinese medicine PHY906 reduces chemotherapy-induced 
gastrointestinal toxicity, Sci Transl Med 2 45ra59. 
[114] D.S. Wishart, Current progress in computational metabolomics, Brief Bioinform 8 
(2007) 279-293. 
[115] V. Shulaev, Metabolomics technology and bioinformatics, Brief Bioinform 7 (2006) 128-
139. 
[116] D.S. Wishart, Human Metabolome Database: completing the 'human parts list', 
Pharmacogenomics 8 (2007) 683-686. 
[117] D.S. Wishart, D. Tzur, C. Knox, R. Eisner, A.C. Guo, N. Young, D. Cheng, K. Jewell, D. 
Arndt, S. Sawhney, C. Fung, L. Nikolai, M. Lewis, M.A. Coutouly, I. Forsythe, P. 
Tang, S. Shrivastava, K. Jeroncic, P. Stothard, G. Amegbey, D. Block, D.D. Hau, J. 
Wagner, J. Miniaci, M. Clements, M. Gebremedhin, N. Guo, Y. Zhang, G.E. 
Duggan, G.D. Macinnis, A.M. Weljie, R. Dowlatabadi, F. Bamforth, D. Clive, R. 
Greiner, L. Li, T. Marrie, B.D. Sykes, H.J. Vogel, L. Querengesser, HMDB: the 
Human Metabolome Database, Nucleic Acids Res 35 (2007) D521-526. 
[118] J.L. Markley, M.E. Anderson, Q. Cui, H.R. Eghbalnia, I.A. Lewis, A.D. Hegeman, J. Li, 
C.F. Schulte, M.R. Sussman, W.M. Westler, E.L. Ulrich, Z. Zolnai, New 
bioinformatics resources for metabolomics, Pac Symp Biocomput (2007) 157-168. 
[119] J. Kopka, N. Schauer, S. Krueger, C. Birkemeyer, B. Usadel, E. Bergmuller, P. Dormann, 
W. Weckwerth, Y. Gibon, M. Stitt, L. Willmitzer, A.R. Fernie, D. Steinhauser, 
GMD@CSB.DB: the Golm Metabolome Database, Bioinformatics 21 (2005) 1635-
1638. 
www.intechopen.com
 
Systems and Computational Biology – Molecular and Cellular Experimental Systems 
 
314 
[120] J.H. Kempen, E. Daniel, J.P. Dunn, C.S. Foster, S. Gangaputra, A. Hanish, K.J. 
Helzlsouer, D.A. Jabs, R.O. Kacmaz, G.A. Levy-Clarke, T.L. Liesegang, C.W. 
Newcomb, R.B. Nussenblatt, S.S. Pujari, J.T. Rosenbaum, E.B. Suhler, J.E. Thorne, 
Overall and cancer related mortality among patients with ocular inflammation 
treated with immunosuppressive drugs: retrospective cohort study, BMJ 339 (2009) 
b2480. 
[121] A. Martinez, A. Castro, I. Dorronsoro, M. Alonso, Glycogen synthase kinase 3 (GSK-3) 
inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and 
inflammation, Med Res Rev 22 (2002) 373-384. 
[122] J.M. Stewart, L. Gera, D.C. Chan, P.A. Bunn, Jr., E.J. York, V. Simkeviciene, B. Helfrich, 
Bradykinin-related compounds as new drugs for cancer and inflammation, Can J 
Physiol Pharmacol 80 (2002) 275-280. 
[123] J.L. Griffin, Understanding mouse models of disease through metabolomics, Curr Opin 
Chem Biol 10 (2006) 309-315. 
[124] K.W. Jordan, L.L. Cheng, NMR-based metabolomics approach to target biomarkers for 
human prostate cancer, Expert Rev Proteomics 4 (2007) 389-400. 
[125] L.L. Cheng, M.A. Burns, J.L. Taylor, W. He, E.F. Halpern, W.S. McDougal, C.L. Wu, 
Metabolic characterization of human prostate cancer with tissue magnetic 
resonance spectroscopy, Cancer Res 65 (2005) 3030-3034. 
[126] J.L. Griffin, R.A. Kauppinen, Tumour metabolomics in animal models of human 
cancer, J Proteome Res 6 (2007) 498-505. 
[127] A. Brazma, P. Hingamp, J. Quackenbush, G. Sherlock, P. Spellman, C. Stoeckert, J. 
Aach, W. Ansorge, C.A. Ball, H.C. Causton, T. Gaasterland, P. Glenisson, F.C. 
Holstege, I.F. Kim, V. Markowitz, J.C. Matese, H. Parkinson, A. Robinson, U. 
Sarkans, S. Schulze-Kremer, J. Stewart, R. Taylor, J. Vilo, M. Vingron, Minimum 
information about a microarray experiment (MIAME)-toward standards for 
microarray data, Nat Genet 29 (2001) 365-371. 
[128] G.A. Churchill, Fundamentals of experimental design for cDNA microarrays, Nat 
Genet 32 Suppl (2002) 490-495. 
[129] H.M. Fathallah-Shaykh, Microarrays: applications and pitfalls, Arch Neurol 62 (2005) 
1669-1672. 
[130] H.M. Fathallah-Shaykh, B. He, L.J. Zhao, A. Badruddin, Mathematical algorithm for 
discovering states of expression from direct genetic comparison by microarrays, 
Nucleic Acids Res 32 (2004) 3807-3814. 
www.intechopen.com
Systems and Computational Biology - Molecular and Cellular
Experimental Systems
Edited by Prof. Ning-Sun Yang
ISBN 978-953-307-280-7
Hard cover, 332 pages
Publisher InTech
Published online 15, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Whereas some â€œmicroarrayâ€ ​ or â€œbioinformaticsâ€ ​ scientists among us may have been criticized as
doing â€œcataloging researchâ€ ​, the majority of us believe that we are sincerely exploring new scientific and
technological systems to benefit human health, human food and animal feed production, and environmental
protections. Indeed, we are humbled by the complexity, extent and beauty of cross-talks in various biological
systems; on the other hand, we are becoming more educated and are able to start addressing honestly and
skillfully the various important issues concerning translational medicine, global agriculture, and the
environment. The two volumes of this book presents a series of high-quality research or review articles in a
timely fashion to this emerging research field of our scientific community.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Shu-Yi Yin and Ning-Sun Yang (2011). Immuno-Modulatory Effects of Phytomedicines Evaluated Using Omics
Approaches, Systems and Computational Biology - Molecular and Cellular Experimental Systems, Prof. Ning-
Sun Yang (Ed.), ISBN: 978-953-307-280-7, InTech, Available from:
http://www.intechopen.com/books/systems-and-computational-biology-molecular-and-cellular-experimental-
systems/immuno-modulatory-effects-of-phytomedicines-evaluated-using-omics-approaches
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
